China Sxt Pharmaceuticals Stock Net Income
| SXTC Stock | USD 0.39 0.01 2.63% |
China SXT Pharmaceuticals fundamentals help investors to digest information that contributes to China SXT's financial success or failures. It also enables traders to predict the movement of China Stock. The fundamental analysis module provides a way to measure China SXT's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to China SXT stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -3.1 M | -3.3 M | |
| Net Loss | -5.2 M | -4.9 M | |
| Net Loss | -3.1 M | -3.3 M | |
| Net Loss | (3.57) | (3.75) | |
| Net Income Per E B T | 0.95 | 0.70 |
China | Net Income |
China SXT Pharmaceuticals Company Net Income Analysis
China SXT's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current China SXT Net Income | (3.1 M) |
Most of China SXT's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, China SXT Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
China Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for China SXT is extremely important. It helps to project a fair market value of China Stock properly, considering its historical fundamentals such as Net Income. Since China SXT's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of China SXT's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of China SXT's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
China Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, China SXT Pharmaceuticals reported net income of (3.1 Million). This is 100.91% lower than that of the Personal Care Products sector and significantly lower than that of the Consumer Staples industry. The net income for all United States stocks is 100.54% higher than that of the company.
China Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses China SXT's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of China SXT could also be used in its relative valuation, which is a method of valuing China SXT by comparing valuation metrics of similar companies.China SXT is currently under evaluation in net income category among its peers.
China SXT Institutional Holders
Institutional Holdings refers to the ownership stake in China SXT that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of China SXT's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing China SXT's value.| Shares | Virtu Financial Llc | 2024-06-30 | 31.6 K | Citadel Advisors Llc | 2024-06-30 | 16.1 K | Baader Bank Inc | 2024-09-30 | 15.2 K | Ubs Group Ag | 2024-06-30 | 12.6 K | Gsa Capital Partners Llp | 2024-09-30 | 12.3 K | Bank Of Montreal | 2024-06-30 | 10 K | Bmo Capital Markets Corp. | 2024-06-30 | 10 K | Qube Research & Technologies | 2024-06-30 | 303 | Acadian Asset Management Llc | 2024-06-30 | 0.0 |
China Fundamentals
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0497 | ||||
| Profit Margin | (1.61) % | ||||
| Operating Margin | 7.34 % | ||||
| Current Valuation | (7.87 M) | ||||
| Shares Outstanding | 4.06 M | ||||
| Shares Owned By Insiders | 16.94 % | ||||
| Shares Owned By Institutions | 2.25 % | ||||
| Number Of Shares Shorted | 105.3 K | ||||
| Price To Earning | 5.73 X | ||||
| Price To Book | 0.11 X | ||||
| Price To Sales | 0.82 X | ||||
| Revenue | 1.93 M | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (2.35 M) | ||||
| Net Income | (3.1 M) | ||||
| Cash And Equivalents | 15.52 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 2.65 M | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 1.31 X | ||||
| Book Value Per Share | 6.28 X | ||||
| Cash Flow From Operations | (1.93 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (3.53) X | ||||
| Number Of Employees | 75 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 1.58 M | ||||
| Total Asset | 23.13 M | ||||
| Retained Earnings | (24.71 M) | ||||
| Working Capital | 5.33 M | ||||
| Net Asset | 23.13 M |
About China SXT Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze China SXT Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China SXT using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China SXT Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:Check out China SXT Piotroski F Score and China SXT Altman Z Score analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (3.53) | Revenue Per Share 2.223 | Quarterly Revenue Growth 0.295 | Return On Assets (0.05) |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.